Business context and reporting period
The supplied filing is AntriaBio, Inc.’s Form 10-Q for the quarter ended December 31, 2014 (the second quarter of its fiscal 2015), filed February 17, 2015. This does not match the request metadata naming Rezolute, Inc.; the summary below reflects the filing itself. AntriaBio describes itself as a preclinical biopharmaceutical company developing sustained-release therapeutics. Its lead candidate, AB101, is a once-weekly basal insulin injection. The company had not generated revenue.
Financial results and position
- Revenue: None. Gross margin and operating margin are not meaningful for this period.
- Expenses and losses: For the quarter, operating expenses were $3.07 million and net loss was $2.94 million, versus $0.65 million and $1.82 million, respectively, in the prior-year quarter. For the six months, operating expenses were $5.30 million and net loss was $5.15 million, versus $1.35 million and $2.64 million. Six-month R&D was $1.68 million, up from none; G&A was $3.63 million, versus $1.35 million.
- Cash flow: Six-month operating cash use was $3.21 million, compared with $0.36 million a year earlier. Investing cash use was $0.32 million; financing provided $6.18 million, primarily from equity issuance. Cash increased by $2.66 million to $8.59 million.
- Liquidity and balance sheet: Current assets were $8.73 million and current liabilities $2.37 million at December 31, 2014; reported working capital was approximately $6.36 million. Total assets were $10.72 million, total liabilities $2.91 million, and accumulated deficit $22.90 million.
- Debt and other obligations: $60,000 of convertible notes remained outstanding, matured, and payable on demand; they continued to accrue 8% interest and remained convertible at the holders’ option. The company also reported lease liabilities and a $1.07 million warrant derivative liability. Minimum rent commitments under the facility and equipment leases totaled approximately $2.18 million.
- Share count: 22.00 million common shares were outstanding at December 31, 2014. The six-month private placement issued 3.74 million shares with warrants and generated approximately $6.2 million net proceeds.
Changes versus prior comparable periods
Losses increased as the company began significant R&D activity, expanded staffing, and incurred higher stock-based compensation and investor-relations costs. Six-month compensation and benefits were $2.73 million, compared with $0.77 million. Financing improved cash, but operating cash use rose materially. The six-month net loss was partly offset by a $153,714 derivative gain; the comparable prior-year period recorded a derivative loss and higher interest expense.
Outlook, risks, and unusual items
- Development objectives: For calendar 2015, management targeted completion of the manufacturing-suite buildout, AB101 toxicology studies in two animal species, an IND filing, a first clinical study in the fourth quarter, and identification of another pipeline candidate. The company expected toxicology studies to begin in March 2015, final results in August, and an IND filing in late September or early October. Suite completion was anticipated by the end of June 2015.
- Funding outlook: Management estimated construction would cost at least $2.5 million, additional manufacturing equipment $1.5–$2 million, and the first AB101 clinical study approximately $4 million. It said at least $8 million of additional funding was needed to support operations through mid-2016 and the clinical proof-of-concept objective. The filing also says current cash and expected operating cash flows would not sustain operations for more than one year and that continued operations depend on raising capital; management disclosed substantial doubt about the company’s ability to continue as a going concern.
- Execution and financing risks: Manufacturing-suite construction, equipment installation, sterile test-batch production, toxicology results, and IND preparation could delay clinical development. Additional equity could materially dilute shareholders; financing availability and acceptable terms were not assured.
- Other items: The company paid $55,000 to acquire PR Pharmaceuticals-related contingent consideration and reported that no further contingent payments were due. It reported no material pending or threatened litigation. Management concluded disclosure controls were ineffective because of a material weakness involving inadequate segregation of duties and the need for a stronger control environment; no material control changes were reported during the quarter.
Important facts for investors to verify
- Confirm the issuer: the filing names AntriaBio, Inc., not Rezolute, Inc.
- Track cash burn, the timing and terms of additional financing, and whether funds cover the stated development plans.
- Monitor manufacturing-suite completion, AB101 material production, toxicology results, IND acceptance, and the planned clinical-study start.
- Assess dilution and potential warrant overhang: 16.10 million warrants were outstanding at December 31, 2014.
- Reconcile an apparent balance-sheet presentation inconsistency: the balance sheet reports stockholders’ equity of $7,817,132, while the equity statement reports $7,817,312.